Stoke Therapeutics Doses First Patient in Phase 1 Trial for Rare Vision Disease ADOA
Event summary
- First patient dosed in Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
- STK-002 is an antisense oligonucleotide designed to upregulate OPA1 protein expression.
- Study is dose-escalating and open-label, enrolling patients aged 6 to 55 with confirmed OPA1 gene variants.
- Primary objectives include assessing safety, tolerability, and exposure in blood.
- Secondary objectives include changes in visual function, ocular structure, and quality of life.
The big picture
Stoke Therapeutics is expanding its RNA medicine approach into a new disease area, leveraging its experience with Dravet syndrome. The Phase 1 trial of STK-002 for ADOA represents a strategic move into the rare disease space, where there are currently no approved treatments. The company's proprietary TANGO approach aims to restore protein expression, potentially offering a disease-modifying therapy for ADOA patients.
What we're watching
- Clinical Progress
- Whether STK-002 demonstrates safety and tolerability in early-stage trials, paving the way for further development.
- Regulatory Pathway
- The pace at which Stoke Therapeutics can advance STK-002 through clinical trials, given its orphan drug designation.
- Market Potential
- How the success of STK-002 could position Stoke Therapeutics in the rare disease and RNA medicine sectors.
Related topics